Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis

Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis

Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ru-ping Cai, Yu-li Xu, Qiang Su
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Cardiology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2021/6657380
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
by: Zehui Jiang, et al.
Published: (2025-05-01)

Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness
by: Adarsh Raja, et al.
Published: (2024-12-01)

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
by: Carlos Escobar, et al.
Published: (2025-07-01)

The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
by: Skala Mamand Jawhar, et al.
Published: (2023-09-01)

Clinical and economic analysis of the use of the medicinal product dapagliflozin in patients with chronic heart failure and type 2 diabetes mellitus
by: M. V. Zhuravleva, et al.
Published: (2024-07-01)

Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study
by: Umut Kocabas, et al.
Published: (2025-02-01)

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Dynamics of chronic heart failure with a low ejection fraction when dapagliflozin is included in standard therapy
by: A. A. Tsareva, et al.
Published: (2024-04-01)

The effects of moxibustion in chronic heart failure patients: a systematic review and meta-analysis
by: Guancheng Chen, et al.
Published: (2025-07-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin following an Admission for Acute Heart Failure
by: Gema Miñana, et al.
Published: (2025-01-01)

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Prevalence and Associated Factors of Frailty in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
by: Longren Wu, et al.
Published: (2025-03-01)

Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway.
by: Jing Zhang, et al.
Published: (2025-01-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure
by: Pongsathorn Gojaseni, et al.
Published: (2024-12-01)

Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
by: Massimo Mapelli, et al.
Published: (2025-03-01)

Dynamics of uric acid concentration against the background of early dapagliflozin use in patients with acute decompensation of heart failure
by: Laura H. Sarieva, et al.
Published: (2024-01-01)

Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients
by: Ahmed Essam Abou Warda, et al.
Published: (2025-04-01)

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure
by: Shodai Kawanami, et al.
Published: (2025-06-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Impact of s acubitril/valsartan on chronic heart failure patients with sleep-disordered breathing: a systematic review and meta-analysis
by: Xuyuan Kuang, et al.
Published: (2025-08-01)

Reverse myocardial remodeling according to cardiac magnetic resonance imaging in patients with heart failure and atrial fibrillation receiving dapagliflozin
by: K. M. Saipudinova, et al.
Published: (2024-10-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Efficacy and safety of Dengzhan Shengmai capsule in the treatment of chronic heart failure: a systematic review and meta-analysis
by: Shenghua Lu, et al.
Published: (2025-02-01)

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF
by: Andrew P. Ambrosy, et al.
Published: (2025-06-01)

Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review
by: Lu Wang, et al.
Published: (2024-12-01)

Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
by: Amro Qaddoura, et al.
Published: (2015-01-01)

Systematic review and meta-analysis of nitrates/nitrites in patients with heart failure or pulmonary hypertension
by: Yujuan Huang, et al.
Published: (2025-07-01)

Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label, randomized controlled trial (the jDAPA-PD study)
by: Mototsugu Tanaka, et al.
Published: (2025-06-01)

Positive experiences of family caregivers of patients with chronic heart failure: protocol for a qualitative systematic review and meta-synthesis
by: Panpan Yang, et al.
Published: (2022-12-01)

Efficacy and safety of puerarin injection as an adjunctive therapy for chronic heart failure: a systematic review and meta-analysis
by: Hesong Fan, et al.
Published: (2025-04-01)

Length of stay and prior heart failure admission in frailty and heart failure: A systematic review and meta‐analysis
by: Konstantinos Prokopidis, et al.
Published: (2025-08-01)

Statins in the treatment of chronic heart failure: a systematic review.
by: Pim van der Harst, et al.
Published: (2006-08-01)

Dapagliflozin combined with methylcobalamin in the treatment of type 2 diabetes mellitus with peripheral neuropathy: a systematic review and meta-analysis
by: Xiao-Long Deng, et al.
Published: (2025-06-01)

Effects of dapagliflozin on heart rate variability, cardiac function, and short-term prognosis in early-onset post-myocardial infarction heart failure
by: Le Zhou, et al.
Published: (2025-01-01)

ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS
by: Lei Zhang, et al.
Published: (2015-12-01)

The impact of telemedicine technologies on the quality of life of patients with heart failure: a systematic review and meta-analysis
by: A. A. Garanin, et al.
Published: (2025-05-01)

Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis
by: Burhanuddin Sohail Rangwala, et al.
Published: (2024-12-01)